If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-06. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The required oxygen functionality was then introduced via epoxidation followed by a Lewis acid-catalyzed SN2′-type ring-opening reaction with allyl alcohol. This led to an intermediate that had previously been converted to Guanacastepene A by other groups. Thus, the formal synthesis could be considered complete.
Fusion: In this method the ingredients are melted together in descending order of their melting points and stirred to ensure homogeneity. Trituration: In this finely subdivided insoluble medicaments are evenly distributed by grinding with a small amount of the base followed by dilution with gradually increasing amounts of the base.
== Therapeutic touch and nursing education == Sokal, in 2006, reported generally accepted estimates of over 80 colleges and universities spread over 70 countries where therapeutic touch is taught, as well as some 80 hospitals in North America where it is practiced. He added that "these figures should be taken with a grain of salt, since both advocates and detractors [...] have an interest in exaggerating its incidence". Owen Hammer and James Underdown of the Independent Investigations Group examined nursing standards in California, where the California Board of Registered Nursing can award registered nurses taking classes in therapeutic touch with continuing education units required for licensure renewal. In 2006, Hammer and Underdown presented the board with the scientific evidence refuting the validity of therapeutic touch as a legitimate treatment, but the board did not change its policy.
Sources: en.wikipedia.org
Clifford insisted that no British troops should be committed for the suppression of the rebellion. In October, Clarke arrived at Wepener at the head of a force of 1,000 cavalry, 600 infantry, five artillery pieces, and 40 wagons. Clarke was aiming to relieve Mafeteng, whose garrison was forced to exchange messages written in Greek, since some Basuto chiefs spoke both English and French. Clarke's advance was slowed by deep mud, and the Basuto cavalry regularly harried the column with rifle fire before withdrawing. On 19 October, the Cape army reached Qalabane, an isolated kop halfway between Wepener and Mafeteng. Lerotholi had positioned 3,000 of his warriors behind a ridge that overlooked a nearby road. The advanced guard of the Cape Mounted Yeomanry came under rifle fire from the kop. Clarke ordered the artillery to fire upon the kop and dispatched 200 men from the 1st Cape Mounted Yeomanry to flank the kop from the left. CMY commander Captain Dalgety ordered his soldiers to dismount and assume an open order formation. Chief Seiso's led a charge of 300 axe-wielding Basuto cavalrymen on Dalgety's unit before the latter was able to reach the crest. The 2nd CMY reinforced Dalgety soon afterwards and captured a nearby village. The Cape army lost 32 killed and seven injured, while the Basuto lost 40 killed. The yeomanry was almost defenseless in hand-to-hand combat, as it was not yet issued bayonets or swords.
A main supply valve with non-return valve, which supplies gas to the main gas supply hose of the umbilical. This is usually a quarter-turn valve, as it must be quick to operate and obvious whether it is open or closed. A pneumofathometer supply valve, which supplies gas to the pneumofathometer for the diver. This valve is usually near the main supply valve but with a different handle. It is usually a needle type valve as it must be finely adjustable, but it must also be large enough to allow a fairly high flow rate, as the air may be used as an alternative breathing air source, or to fill small lift bags. A pneumofathometer gauge is connected to the pneumo line. This is a high resolution pressure gauge calibrated in feet sea water (fsw) and/or metres sea water (msw). and is used to measure the depth of the diver by allowing air to flow through the pneumo hose and out the end attached to the diver. When the air supply is shut off, and the flow stops, the gauge indicates the pressure at the open end at the diver. Each pneumofathometer gauge has an overpressure valve to protect it against gas supply at higher pressure than it is designed to take. This is essential as the main supply pressure is significantly higher than the maximum depth pressure on the pneumo gauge. There is also often a snubbing valve or orifice between the pneumo line and the gauge to restrict flow into the gauge and ensure that the overpressure valve can adequately relieve the pressure.
== Applications of SSMS == Spark source mass spectrometry has been used for trace analysis and multielement analysis applications for highly conducting, semiconducting, and nonconducting materials. Some examples of SSMS applications are the trace element analysis of high-purity materials, multielement analysis of elements in technical alloys, geochemical and cosmochemical samples, biological samples, industrial stream samples, and radioactive material.
=== Permethrin === Permethrin, a pyrethroid insecticide, is the most effective treatment for scabies, and remains the treatment of choice. It is applied from the neck down, usually before sleep, and left on for about 8 to 14 hours, then washed off in the morning. Care should be taken to coat the entire skin surface, not just symptomatic areas; any patch of skin left untreated can provide a "safe haven" for one or more mites to survive. One application is normally sufficient, as permethrin kills eggs, hatchlings, and adult mites, though many physicians recommend a second application three to seven days later as a precaution. Crusted scabies may require multiple applications or supplemental treatment with oral ivermectin (below). Permethrin may cause slight irritation of the skin that is usually tolerable. In recent years, concern has grown regarding the development of permethrin-resistant scabies. 2022 studies performed in Kuşadası, Turkey showed in cases where patients failed to improve with 5% permethrin, 100% of scabies mites analyzed were sensitive to in-vitro 5% permethrin, suggesting that lack of efficacy could be due to treatment non-compliance rather than true resistance. However, a 2024 study published in Salzburg, Austria revealed permethrin resistant-scabies in nearly 3 out of 4 cases studied. In this population, treatment with benzyl benzoate had a considerably higher cure rate. Additional studies will be needed to confirm the presence of permethrin-resistance and to determine its epidemiology.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.